LEADER 01223nam a2200253 i 4500 001 991000886829707536 005 20020507102801.0 008 930519s1973 it m 0|| | ita d 035 $ab10143567-39ule_inst 035 $aLE00638586$9ExL 040 $aDip.to Fisica$beng 100 1 $aRizzelli, Luigi$0461626 245 10$aDeterminazione del piano equatoriale galattico mediante lo studio della distribuzione degli ammassi di galassie. Tesi di laurea /$claureando Luigi Rizzelli ; relatori Francesco Bertola e Massimo Capaccioli 260 $aLecce :$bUniversità degli Studi. Facoltà di Scienze. Corso di laurea in Fisica,$ca.a. 1972-73 300 $a93 p., tav. ripieg. ;$c30 cm 502 $aTesi. Università degli Studi di Lecce, 1973 700 1 $aBertola, Francesco 700 1 $aCapaccioli, Massimo 907 $a.b10143567$b02-04-14$c27-06-02 912 $a991000886829707536 945 $aLE006 T66$g1$i2006000096621$lle006$o-$pE0.00$q-$rn$so $t0$u0$v0$w0$x0$y.i10170649$z27-06-02 996 $aDeterminazione del piano equatoriale galattico mediante lo studio della distribuzione degli ammassi di galassie. Tesi di laurea$9186941 997 $aUNISALENTO 998 $ale006$b01-01-93$cm$da $e-$fita$git $h0$i1 LEADER 04954nam 2200589 450 001 9910137205703321 005 20230621141045.0 010 $a9782889193806$b(ebook) 035 $a(CKB)3710000000520136 035 $a(SSID)ssj0001666236 035 $a(PQKBManifestationID)16454664 035 $a(PQKBTitleCode)TC0001666236 035 $a(PQKBWorkID)14999734 035 $a(PQKB)11443880 035 $a(WaSeSS)IndRDA00056267 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/42640 035 $a(EXLCZ)993710000000520136 100 $a20160829d2014 uy | 101 0 $aeng 135 $aur||#|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCancer immunotherapy & immuno-monitoring $emechanism, treatment, diagnosis, and emerging tools /$ftopic editors: Chao Ma, Rong Fan and Antoni Ribas 210 $cFrontiers Media SA$d2014 210 31$aBrazil :$cFrontiers Media SA,$d2014 215 $a1 online resource (97 pages) $cillustrations; digital, PDF file(s) 225 0 $aFrontiers Research Topics 300 $aBibliographic Level Mode of Issuance: Monograph 320 $aIncludes bibliographical references. 330 $aIn the past decade, significant progresses have taken place in the field of cancer immunotherapeutics. Tumor-targeting or adjuvant immunotherapies are being developed for most human cancers including melanoma, prostate cancer, glioblastoma, sarcoma, lung carcinoma and hepatocellular carcinoma. New immunotherapeutics, such as Ipilimumab (anti-CTLA-4), have finished human trials and are approved by the US Food and Drug Administration (FDA) for clinical treatment; cell-based immunotherapies such as adoptive cell transfer (ACT) have either been approved (i.e., sipuleucel-T) for the treatment of selected neoplastic malignancies or reached the stage of phase II/III clinical trials. Immunotherapetics has become a sophisticated field. Multimodal therapeutic regimens comprising several functional modules (up to 5 in the case of ACT) have been developed to provide more focused therapeutic responses with improved efficacy and reduced side effects. Despite the tremendous developments, a major challenge mains: the lack of effective and clinically-applicable methods. Due to the complex immunological responses of patients that involve both the organs with neoplastic lesion and the whole immune system, it is difficult to provide comprehensive assessment of therapeutic efficacy and mechanism in patients. Despite the rapid adaptation of advanced medical imaging modalities such as MRI and PET/CT scan and the gold standard pathological examination, there is still unmet demand in the clinic to best evaluate cancer-specific cellular immunity and functions. Flow cytometry analysis has modernized hematology and immunology, and is currently being adapted to clinical immune monitoring through a multi-center endeavour in the US. The study aims to normalize, standardize, and implement flow cytometry-based cellular immunity assay in routine clinical tests. In parallel, new technologies including single cell polyfunctional analysis and immunophenotyping microchip are being developed for rapid, informative, and longitudinal monitoring of immune response to anti-cancer treatment in the clinical settings, shedding new light to future clinical trials of cancer immunotherapies. These technologies were designed to address the major challenges caused by the complexity and functional heterogeneity of cancer biology and cellular immunity, and allow for comprehensive survey of both tumor and the immune system to identify their mechanistic interplay in response to cancer immunotherapy. In addition, new computational tools are required to integrate high dimensional data sets from comprehensive, single-cell level measurements of patient?s immune responses and render most accurate and definitive diagnostic decision facilitated by new immune monitoring tools. This new generation of informative, personalized clinical diagnostic tools will likely contribute to new understanding of therapy mechanism, pre-treatment stratification of patients, ongoing therapeutic monitoring and assessment. 517 1 $aCancer immunotherapy and immuno-monitoring 606 $aOncology$2HILCC 606 $aMedicine$2HILCC 606 $aHealth & Biological Sciences$2HILCC 610 $aimmune assessment 610 $asingle cell analysis 610 $acancer immunotherapy 610 $atumor immunity 610 $aimmune suppression 615 7$aOncology 615 7$aMedicine 615 7$aHealth & Biological Sciences 700 $aChao Ma$4auth$01366910 702 $aFan$b Rong 702 $aMa$b Chao 702 $aRibas$b Antoni 801 0$bPQKB 801 2$bUkMaJRU 912 $a9910137205703321 996 $aCancer immunotherapy & immuno-monitoring$93389429 997 $aUNINA LEADER 04496nam 22006375 450 001 9910682566003321 005 20230824135507.0 010 $a3-031-24655-1 024 7 $a10.1007/978-3-031-24655-5 035 $a(MiAaPQ)EBC7216773 035 $a(Au-PeEL)EBL7216773 035 $a(CKB)26271469000041 035 $a(DE-He213)978-3-031-24655-5 035 $a(PPN)269100121 035 $a(EXLCZ)9926271469000041 100 $a20230316d2023 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCOVID-19, Tourist Destinations and Prospects for Recovery $eVolume Two: An African Perspective /$fedited by Kaitano Dube, Ishmael Mensah, Lazarus Chapungu 205 $a1st ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (281 pages) 311 08$a3-031-24654-3 327 $aPart1. Background and Introduction -- Chapter1. Tourism and COVID-19: An African perspective -- Part2. Impact of COVID-19 on African tourist destinations -- Chapter2. The effects of COVID-19 pandemic on small-scale hospitality and tourism businesses in coastal communities in Ghana -- Chapter3. Navigating the Impact of COVID-19 on Tourism in Zambia -- Chapter4. Exploring trends of South African accommodation occupancy during COVID- 19 -- Chapter5. The impact of COVID-19 on the hotels as quarantine destinations -- Part3. COVID-19 recovery and resilience of tourist destinations in Africa -- Chapter6. Evaluation of the efficacy of the COVID-19 recovery plans for tourism: Limpopo Province in South Africa -- Chapter7. Impact, Recovery and Resilience of the Events sector from COVID-19 crisis: Lessons from Zimbabwe -- Chapter8. Prospects for tourism recovery in Kariba town in the context of COVID- 19 -- Chapter9. The resilience of Private Protected Areas Lodges: Lessons from South Africa amid COVID-19 -- Part4. Tourism recovery Strategies for African tourist destinations -- Chapter10. Impacts of COVID-19 on Emerging Tourist Destinations and Recovery Strategies: The Case of Ghana -- Chapter11. The Utilisation of Virtual Reality as a Recovery Strategy to Stimulate Travel Intentions of students amidst the Covid-19 Pandemic in South Africa -- Chapter12. COVID-19 and rural tourism destinations in South Africa: Impact, transformation opportunities and potential -- Chapter13. Aviation recovery, resilience, challenges, and opportunities a focus on Western Cape province, South Africa -- Part5. Conclusion and Recommendations -- Chapter14. The future of tourism in a post-COVID-19 era: Practical and policy perspectives. 330 $aDespite the fact that the African tourism industry is prone to disturbances such as diseases, extreme weather events, civil unrest, wars, and other shocks, nothing could have prepared this destination for the devastating effect of the COVID-19 pandemic. In the absence of government or international agency budget support, the pandemic challenged the African tourism market to its core. The focus of this book is to assess the impact of the COVID-19 pandemic on the African tourism destination market as well as its prospects for recovery. A chapter written by the editorial team introduces the book. Following the introduction, the book offers chapters evaluating the pandemic's impact on African tourism. Chapters in the second part of the book discuss tourism recovery and how some destinations have survived the pandemic. The book concludes with a chapter providing policy recommendations and practical implementation advice. The book is part of a 3 volume series. 606 $aTourism 606 $aManagement 606 $aGeography 606 $aBusiness 606 $aAfrica 606 $aTourism Management 606 $aGeography 606 $aAfrican Business 615 0$aTourism. 615 0$aManagement. 615 0$aGeography. 615 0$aBusiness. 615 0$aAfrica. 615 14$aTourism Management. 615 24$aGeography. 615 24$aAfrican Business. 676 $a338.4791 676 $a338.4791 700 $aDube$b Kaitano$01274888 702 $aMensah$b Ishmael 702 $aChapungu$b Lazarus 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910682566003321 996 $aCOVID-19, tourist destinations and prospects for recovery$93407407 997 $aUNINA